TapImmune Inc.  

(Public, OTCMKTS:TPIV)   Watch this stock  
Find more results for David Bonfiglio
0.357
-0.012 (-3.38%)
Sep 1 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.35 - 0.37
52 week 0.12 - 1.71
Open 0.36
Vol / Avg. 521,078.00/804,713.00
Mkt cap 16.49M
P/E     -
Div/yield     -
EPS -0.71
Shares 46.14M
Beta 1.92
Inst. own 12%
Sep 9, 2015
TapImmune Inc at Rodman & Renshaw Global Investment Conference - 3:00PM EDT - Add to calendar
  

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -3093.08% -20487.66%
Return on average equity - -
Employees 1 -
CDP Score - -

Address

1551 Eastlake Ave E Ste 100
SEATTLE, WA 98102-7402
United States - Map
+1-206-5047278 (Phone)

Website links

Description

TapImmune Inc. is a clinical-stage immunotherapy company. The Company is engaged in the development of peptide, gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease. The Company combines a set of technologies to improve the ability of the cellular immune system to destroy diseased cells. The Company’s technologies include peptide antigen technologies and DNA expression technologies; Polystart, and TAP. The Company is focused on the clinical development and testing of its product candidates. The Company’s standard therapies for its initial targets in cancer include surgery, radiation therapy and chemotherapy. The Company combines a set of technologies to improve the ability of the cellular immune system to destroy diseased cells. These are peptide antigen technologies and DNA expression technologies, Polystart and TAP.

Officers and directors

Glynn Wilson Ph.D. Chairman of the Board, Chief Executive Officer, Chief Financial Officer, Secretary
Age: 68
Mark Reddish Vice President Development
Age: 60
John N. Bonfiglio Ph.D. Director
Age: 60
David Laskow-Pooley Director
Age: 58
Sherry Grisewood CFA Independent Director
Age: 62